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Abstract 
Background: Maternal obesity is associated with several adverse pregnancy outcomes. This study was conducted 
aiming to evaluate maternal levels of adipokines and insulin in pregnancies complicated by overweight and obesity 
and its correlations with maternal and fetal outcomes.
Methods: This cross-sectional study included 72 mother–newborn pairs. Mothers were classified as having normal 
weight (n = 23), overweight (n = 18), and obesity (n = 31). Maternal adiponectin, leptin, resistin and insulin levels 
at the end of pregnancy were compared among groups and correlated with maternal and perinatal outcomes. Data 
were analyzed by ANOVA and correlation tests, with a p value <0.05 being considered as significant.
Results: Obese pregnant women showed higher leptin levels (p = 0.0021). Leptin levels were positively correlated 
with prepregnancy body mass index—BMI (r = 0.57), gestational (37 or 38 weeks of gestation) BMI (r = 0.39), hyper-
tension (r = 0.27), and hyperglycemia (r = 0.30), and negatively associated with newborns’ abdominal circumference 
(r = −0.25). Adiponectin concentrations were negatively correlated with gestational BMI (r = −0.29) and newborns’ 
cephalic circumference (r = −0.27) and positively correlated with birth weight (r = 0.23). Insulin concentrations cor-
related positively with prepregnancy BMI (r = 0.38), gestational BMI (r = 0.24) and maternal hyperglycemia (r = 0.26).
Conclusions: Our findings support the relationship between markers of obesity and maternal–fetal outcomes. 
Maternal insulin and adipokines levels showed an independent relationship with mother and newborns outcomes, 
respectively. In this studied population, the results indirectly reinforce the importance of maternal weight control 
before and during pregnancy to avoid adverse outcomes to mother and their newborns.
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Background
In recent years the endocrine nature of adipose tissue has 
been widely recognized. Its cells synthesize and release a 
number of substances such as many types of adipokines. 
Adipokines are primarily secreted from adipose tissue 
and function as important regulators of appetite, glucose 
homeostasis, immune function, arterial blood pressure 
and blood coagulation [1–3].
Growing evidence has pointed to a putative and causa-
tive relationship between obesity and inflammation. 
An increase in adipose tissue and consequently in adi-
pokines production triggers a series of physiopathologic 
processes associated to the genesis of obesity-related 
pathologies. The production and release of adipokines or 
inflammatory cytokines characterize obesity as a chronic 
inflammatory state [1, 4–7]. In the last decade, different 
adipokines types have been identified, such as leptin, adi-
ponectin, adipsin, resistin, tumoral necrosis factor alpha 
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interleukin (IL) 1β, IL-6 and IL-8, insulin-like growth 
factor 1 (IGF-1), monocyte chemo attractant protein-1 
(MCP-1) and visfatin. Except for adiponectin, the pro-
duction and secretion of these substances is proportional 
to the degree of obesity. A number of these adipokines, 
such as adiponectin, leptin, TNF-α, resistin, PAI-1, IL-6 
and MCP-1, were found to be directly related to insulin 
resistance and associated morbidities [8–11].
In pregnant women, several metabolic changes such as 
progressive increase and redistribution of maternal adi-
pose tissue occur to ensure continuous nutrient supply 
to fetal development. This affects a series of metabolic 
functions that characterize a state of dysmetabolism 
with consequent increase of the risk for adverse preg-
nancy outcomes [5, 8, 12, 13]. Hormones produced by 
the placenta, particularly in the second and third trimes-
ters of pregnancy, generally antagonize insulin action, 
thereby establishing insulin resistance in parallel with 
an increase in the production of this hormone [14, 15]. 
It is thought that adipokines participate in the process of 
insulin resistance during pregnancy, that may be related 
to the occurrence of gestational diabetes mellitus (GDM), 
preeclampsia (PE) and intrauterine growth restriction 
(IUGR). Insulin resistance in pregnancy has been par-
ticularly associated with adiponectin and leptin, which 
are secreted only by the adipose tissue, and IL-6 and 
TNF-α, which are also secreted by the adipose tissue and 
other cells [12, 14, 16].
Among adipokines, leptin is known as the “satiety hor-
mone” given that it inhibits food intake and stimulates 
energy expenditure through activation of receptors in 
the hypothalamus. High leptin levels are found in obese 
people, possibly because they exhibit resistance to the 
action of this hormone [17, 18]. Adiponectin and resistin 
are adipocytokines with antagonistic actions. Adiponec-
tin increases insulin sensitivity, whereas resistin increases 
insulin resistance [18–20].
Obesity and pregnancy play individual roles in the 
development of chronic inflammation and insulin resist-
ance, and their combination can be particularly harmful 
to the mother and the fetus [21, 22]. Many gaps exist in 
the understanding the role of obesity during pregnancy 
and the causal relationship with associated disorders. It 
is not known which problems arise from obesity itself 
and which are a result of unhealthy lifestyle such as sed-
entarism and use of an inadequate diet, which, in turn, 
can promote obesity [11, 23, 24]. Likewise, the lack of 
individualization in the studies, considering only over-
weight or obese mothers without hypertension, hypergly-
cemia or insulin resistance conditions, may change these 
results.
To clarify this scenario, adipokines deserve deeper 
investigation given their potential role as biomarkers of 
obesity and insulin resistance in pregnancy, and therefore 
perinatal outcomes.
The present study evaluated the serum levels of adi-
pokines (adiponectin, leptin and resistin) and insulin in 
overweight and obese pregnant women and correlated 
them with maternal and perinatal outcomes.
Methods
Study design and subjects
We conducted a cross-sectional study with 72 mother-
newborn pairs referred and treated in Diabetes and Preg-
nancy Care Service of Botucatu Medical School—UNESP 
(SEDG-FMB/UNESP). The research was approved by 
the Human Research Ethics Committee of the Medical 
School of Botucatu (CEP-FMB/UNESP). All included 
subjects signed the written informed consent.
The women were classified according to prepregnancy 
BMI into normal weight (18.5–24.9 kg/m2; n = 23), over-
weight (25.0–29.9 kg/m2; n =  18) and obese (≥30.0 kg/
m2; n  =  31) [24]. Underweight women and those with 
multiple pregnancies or malformed fetus were excluded 
from the study.
Studied variables
Pregnant women enrolled in the study were examined at 
their first prenatal (before the 20th gestational week) and 
pre-birth visit (37–38th gestational weeks). They pro-
vided information on their age, number of pregnancies, 
prepregnancy BMI, smoking habits and preexistence of 
chronic arterial hypertension and diabetes mellitus. In 
the pre-birth visit (37–38th gestational weeks) maternal 
body weight, height and blood pressure were evaluated 
according to the standardization of the Brazilian Ministry 
of Health [25]. Gestational BMI, weight gain, hyperten-
sion complicating pregnancy (yes/no), GDM and mild 
gestational hyperglycemia (MGH) (yes/no) [26–28] were 
associated with maternal adiponectin, leptin, resistin and 
insulin levels in the pre-birth period (37–38th gestational 
weeks).
The newborns were examined in order to evalu-
ate gestational age at birth by the New Ballard score, 
weight to gestational age ratio, ponderal index [(weight/
length3)*100], length as well as head, thoracic and 
abdominal circumferences. These evaluations have been 
conducted by a specialized pediatrician and followed the 
normalization of our Service, including the New Bal-
lard score. All these variables also were associated with 
maternal adiponectin, leptin, resistin and insulin levels in 
the pre-birth period (37–38th gestational weeks).
Collection of maternal blood and analysis of adipokines
Maternal blood samples were collected at in Vacutainer 
tubes (Becton–Dickinson, USA) and centrifuged at 4  °C 
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for 15  min at 1000×g. The serum samples were stored 
at −80  °C until adiponectin, leptin, resistin and insulin 
analysis were performed using multiplex ELISA assays 
(Millipore Corporation, Massachusetts, USA).
Subjects’ follow‑up
Pregnant women with prepregnancy type 1 and type 
2 diabetes or those who showed risk of GDM or MGH 
development [27, 28] were referred to the SEDG-FMB/
UNESP. According to the standard protocol used by our 
service, those pregnant women that did not have the 
diagnosis of diabetes, performed a 75 g oral glucose toler-
ance test and had their glycemic profile (GP) determined, 
between 24 and 26 gestation weeks, to confirm or not 
the diagnosis GDM or MGH [27, 28]. Pregnant women 
with MGH presented positive screening for GDM, nega-
tive diagnosis for GDM but with hyperglycemia detected 
in the GP [27]. According to our center’s routine proto-
col, diabetic pregnant women (type 1-DM or type 2-DM) 
were immediately managed with glycemic control, indi-
vidualized nutritional intervention, and light to moder-
ate-intensity exercise program (most frequently walking 
for 30 min five times a week). Insulin therapy was always 
maintained (DM-1) or introduced in substitution to oral 
antidiabetics (DM-2) [27]. Pregnant women who were 
normoglycemic, but were overweight or obese, received 
counseling about the importance of lifestyle changes to 
prevent GDM and MGH, and were promptly assigned to 
individualized nutritional guidance, walking for 30  min 
five times a week for weight control during pregnancy. 
Regardless of these preventive measures, all normogly-
cemic pregnant women underwent glucose tolerance 
(75 g-OGTT) and glycemic profile (GP) testing between 
24 and 28 weeks of pregnancy for confirmation or ruling 
out of GDM and MGH. Pregnant women with confirmed 
GDM or MGH were treated according to the same pro-
tocol, relative to diet and exercise, aiming to achieve gly-
cemic control, and insulin therapy was introduced when 
necessary. Glycemic control and management of diabetes 
were evaluated by 24-h GP (fasting, pre- and post- pran-
dial glycemic levels) performed at 2-week intervals until 
week 32, and weekly until delivery. The glycemic mean 
(GM), calculated by the average of the glycemic levels 
evaluated in the GP, was used to classify the quality of 
maternal glycemic control in adequate (GM  <  120  mg/
dL) or inadequate (GM ≥ 120 mg/dL) [27–30].
Statistical analysis
Data obtained in the medical visits were regularly 
exported to Microsoft Excel spreadsheets. Statistical 
analyses were performed using the SAS package for Win-
dows, version 9.2. Adipokines and insulin data were eval-
uated by ANOVA, followed by the Tukey–Kramer test 
for multiple comparisons. Data correlation was tested 
using Pearson or Spearman correlation tests according 
to distribution normality. Finally, a multiple regression 
analysis was performed to identify the independent fac-
tors to mother and newborn outcomes. The statistical 
significance was set at 0.05 for all the tests.
Results
According to prepregnancy BMI, out of the 72 pregnant 
women evaluated, 23 (31.9  %) had normal weight, 18 
(25.0  %) were overweight, and 31 (43.1  %) were obese. 
Independently of nutritional status, most of the pregnant 
women had between 20 and 35  years old, and at least 
two previous pregnancies. All types of arterial hyper-
tension complicating pregnancy were observed in 33 
(45.8  %) of studied population. A proportion of 16.7  % 
was smoker and 48 (66.7  %) exhibited some form of 
hyperglycemia, which was diagnosed as preexisting dia-
betes (DM2 = 16.7 %), GDM (50.0 %) or MGH (33.3 %). 
Hypertension and diabetes were more frequently associ-
ated with overweight and obesity (Table 1).
Maternal and newborn outcomes are shown in Table 2. 
As indicated by gestational BMI, out of the 72 pregnant 
women evaluated at the end of pregnancy, 17 (23.6 %) of 
the women had normal weight, 17 (23.6  %) were over-
weight, and 38 (52.8  %) obese. Considering gestational 
BMI, 8/23 (34.8  %) prepregnancy normal weight were 
Table 1 Profile of  the pregnant women, according to pre­
pregnancy BMI classes
BMI body mass index, PE preeclampsia, DM-2 type 2 diabetes mellitus, GDM 









 <19 9 (39.1) 1 (5.5) 0 (0.0)
 20–35 12 (52.2) 12 (66.7) 24 (77.4)
 >35 2 (8.7) 5 (27.8) 7 (22.6)
Number of pregnancies
 1 9 (39.1) 3 (16.7) 3 (9.7)
 ≥2 14 (60.9) 15 (83.3) 28 (90.3)
Smoking 5 (21.7) 0 (0.0) 7 (22.6)
Hypertension (n = 33) 3 (13.0) 9 (50.0) 21 (67.7)
 Chronic hypertension 0 (0.0) 1 (3.0) 10 (30.3)
 Preeclampsia 2 (6.0) 6 (18.2) 8 (24.2)
 Chronic hypertension + PE 0 (0.0) 0 (0.0) 6 (18.2)
 Gestational hypertension 1 (3.03) 2 (6.1) 3 (9.7)
Diabetes mellitus (n = 48) 6 (26.1) 11 (61.1) 31 (100.0)
 DM­2 0 (0.0) 3 (27.3) 5 (16.1)
 GDM 2 (33.3) 4 (36.4) 18 (58.1)
 MGH 4 (66.7) 4 (36.4) 8 (25.8)
Page 4 of 8Vernini et al. Diabetol Metab Syndr  (2016) 8:68 
classified as overweight or obese, 16/18 (88.9 %) prepreg-
nancy overweight as overweight or obese, and 31/31 
(100.0 %) prepregnancy obese were overweight or obese. 
Of the 72 newborns, 97.2  % were born to term, and 
80.6  % had normal weight. Only one was underweight 
(<2500  g) and 8.3  % were classified as large for gesta-
tional age. Figure  1 shows adiponectin, leptin, resistin, 
and insulin levels according to weight status. Compared 
to normal weight pregnant women, leptin levels were sig-
nificantly higher in obese women (p = 0.0021).
The correlation between maternal outcomes and mark-
ers of insulin resistance is shown in Table  3. Adiponec-
tin levels were negatively correlated with gestational BMI 
(r = −0.29, p =  0.013), and leptin levels positively cor-
related with prepregnancy BMI (r  =  0.57, p  <  0.0001), 
gestational BMI (r  =  0.39, p  =  0.0007), hyperglyce-
mia (r =  0.31, p =  0.0086) and hypertension (r =  0.27, 
p = 0.0196). Insulin levels were positively correlated with 
prepregnancy BMI (r  =  0.38, p  =  0.0009), gestational 
BMI (r = 0.24, p = 0.0466) and hyperglycemia (r = 0.26, 
p  =  0.0252). Resistin levels were not correlated with 
the evaluated maternal outcomes. Multiple regression 
analysis confirmed only one independent relationship 
that is maternal insulin levels with prepregnancy BMI 
(p  =  0.0343) and weight gain (p  =  0.0417), and a ten-
dency with gestational BMI (p = 0.0570) (Table 4).
Relative to newborn outcomes, maternal adiponectin 
levels were positively correlated with newborns weight 
(r  =  0.23, p  =  0.0487) and inversely correlated with 
newborns head circumference (r = −0.27, p =  0.0216). 
Leptin levels were inversely correlated with abdominal 
circumference (r = −0.25, p =  0.0350). Maternal resis-
tin and insulin levels were not correlated with newborns 
measures (Table  3). In the multiple regression analysis, 
Table 2 Maternal and newborn outcomes, according to prepregnancy BMI classes








 Gestational BMI (kg/m2)
  Adequate 15 (65.2) 2 (11.1) 0
  Overweight 6 (26.1) 9 (50.0) 2 (6.5)
  Obesity 2 (8.7) 7 (38.9) 29 (93.5)
Newborn
 GA at birth (new Ballard score)
  <37 weeks 0 1 (5.6) 1 (3.2)
  ≥37 weeks 23 (100.0) 17 (94.4) 30 (96.8)
 Weight (g)
  <2500 0 0 1 (3.2)
  2500–4000 21 (91,3) 17 (94.4) 27 (87.1)
  ≥4000 2 (8.7) 1 (5.6) 3 (9.7)
 Weight to GA ratio
  Small (SGA) 2 (8.7) 4 (22.2) 2 (6.4)
  Adequate (AGA) 19 (82.6) 13 (72.2) 26 (83.9)
  Large (LGA) 2 (8.7) 1 (5.6) 3 (9.7)
Normal weight Overweight Obese
Mean ± SD Mean ± SD Mean ± SD
Maternal
 Weight gain (kg) 14.6 ± 4.5 13.8 ± 6.1 10.4 ± 8,1
Newborn
 Weight (g) 3340 ± 462.8 3220.6 ± 430.7 3333.9 ± 492.2
 Ponderal index (g/cm3) 2.8 ± 0.3 2.8 ± 0.3 2.9 ± 0.3
 Length (cm) 48.9 ± 2.5 48.4 ± 1.7 48.5 ± 2,1
 Head circumference (cm) 34.5 ± 1.7 34.5 ± 1.5 34.9 ± 1,5
 Thoracic circumference (cm) 33.6 ± 1.9 33.0 ± 1.6 33.3 ± 2.2
 Abdominal circumference (cm) 31.9 ± 2.0 31.4 ± 1.8 34.9 ± 1.5
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only leptin levels remained as independent variable asso-
ciated with the abdominal circumference of the newborn 
(p = 0.0270) (Table 4).
Discussion
In this study, we have found significant associations 
between adipokines and insulin levels with maternal and 
newborn outcomes. Leptin levels increased in obese preg-
nant women, showing a positive correlation with mater-
nal BMI, hyperglycemia and hypertension and an inverse 
correlation with newborn abdominal circumference. Adi-
ponectin levels, in turn, were negatively correlated with 
gestational BMI and newborns head circumference, and 
positively correlated with weight at birth. Resistin levels 
were not associated with any maternal or fetal outcomes. 
Also, insulin levels were positively related to weight sta-
tus and maternal hyperglycemia, but not associated with 
newborn outcomes. Finally, the multiple regression analy-
sis showed that, in this pregnant women population, only 
maternal insulin levels were independently associated to 
prepregnancy BMI and maternal weight gain, with a ten-
dency in gestational BMI (p = 0.0570). Likewise, only lep-
tin levels remained as an independent variable with the 
abdominal circumference of the newborns.
The positive association between insulin and prepreg-
nancy BMI (r = +0.38), gestational BMI (r = +0.24), and 
hyperglycemic disorders (r = +0.26) met the metabolic 
syndrome diagnosis criteria, whose physiopathologic 
basis is the association between obesity and insulin 
resistance [31]. The association between metabolic syn-
drome and gestational hyperglycemia was identified by 
Bo et  al. [32] and recently reproduced by our research 
group [33, 34]. In our study the results were not differ-
ent; pregnant women with overweight or obesity showed 
more hypertension and hyperglycemic disorders, and 
insulin levels were positively correlated with prepreg-
nancy BMI, gestational BMI, and hyperglycemia. More-
over, insulin levels remained as an independent variable 
associated with maternal BMI and weight gain during 
pregnancy.
Leptin is known as the “satiety hormone” given that it 
inhibits food intake and stimulates energy expenditure 
through activation of receptors in the hypothalamus. 
High leptin levels are found in obese people, possibly 
because they exhibit resistance to the action of this hor-
mone [17, 18]. In the present study, leptin levels were 
significantly higher in obese mothers, exhibiting a direct 
association with their BMI (r  =  +0.56 prepregnancy; 
r  =  +0.38 gestational period), hyperglycemic disorders 
(r  =  +0.31), and maternal hypertension (r  =  +0.27). 
These results confirm the role of leptin in energy metabo-
lism, inflammatory state, and insulin resistance associ-
ated with obesity, that has already been found in other 
studies [6, 35, 36].
Fig. 1 Adiponectin, leptin, resistin and insulin levels according to weight classes of the pregnant women. (Values as mean ± standard error of the 
mean; *p < 0.05—ANOVA, followed by the Tukey–Kramer test)
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Adiponectin and resistin are adipocytokines with antag-
onistic actions. Adiponectin increases insulin sensitivity, 
while resistin increases insulin resistance [19, 20]. For 
some authors, resistin is a marker of maternal hyperglyce-
mia, increases in late pregnancy and during the immediate 
post-birth period, and is associated with the HOMA-
IR index [10, 15, 37, 38]. Conversely, other authors have 
found no differences in serum resistin levels in pregnant 
women with GDM, although they show higher BMI and 
higher levels of insulin resistance markers [39].
In the present study, the negative association between 
adiponectin levels and gestational BMI (r = −0.28) sug-
gests that the higher the degree of obesity, the higher the 
insulin resistance, with lower adiponectin and higher 
resistin levels expected. Despite this, our results showed 
that adiponectin and resistin levels exhibited no dif-
ferences among maternal BMI classes. This apparent 
controversy has already been described in the litera-
ture. Adiponectin concentrations were lower in insulin-
resistant states such as obesity and type 2 DM [40] and 
pregnancy complicated by GDM [8, 23]. In contrast, 
adipocytokines levels (including adiponectin, leptin, and 
resistin), although associated with HOMA-IR, had no 
difference among normal or intermediate tolerance glu-
cose and GDM pregnant women [19]. Except for leptin 
levels, a recent study also showed no difference in mater-
nal levels of adiponectin and resistin between obese and 
non-obese pregnant women [41]. In our study, over-
weight or obese mothers showed 85.7 % (42/49) of hyper-
glycemic disorders; thus maternal obesity associated with 
hyperglycemia and insulin resistance could explain these 
results. The controversy in the literature therefore per-
sists and may be more explored. Perhaps, the individual 
analysis of overweight or obese pregnant women, with 
and without diabetes, may solve this question.
Regarding our perinatal results, adiponectin was posi-
tively associated with fetal weight (r = +0.23) and neg-
atively with head circumference (r = −0.27), and leptin 
was negatively correlated with abdominal circumference 
(r  =  −0.25). Adiponectin levels were statistically simi-
lar in normal, overweight, and obese mothers and only 
maternal leptin levels were statistically different and 
defined as an independent variable to fetal abdominal 
circumference. Pregnant women who are obese or have 
GDM typically have low circulating levels of adiponectin 
associated with increased fetal growth [7, 8, 42]. There-
fore, the positive association between maternal adiponec-
tin and fetal weight, as well as the negative association 
between maternal adiponectin and head circumference, 
observed in our study, was not expected.
Table 3 Correlation analysis, coefficient (r) and  p value, 
for  the relationship between  adipokine/insulin levels 
and maternal–newborn variables
Statistically significant results (p < 0.05) highlighted in italic
DM prepregnancy and gestational diabetes, MGH mild gestational 
hyperglycemia
a Pearson’s correlation test





 Prepregnancy BMIa (r) 0.0522 0.5689 −0.1378 0.3843
p 0.6630 <0.0001 0.2483 0.0009
 Gestational BMIb (r) −0.2893 0.3886 −0.0720 0.2354
p 0.0137 0.0007 0.5477 0.0466
 Weight gaina (r) −0.1742 0.0948 −0.0620 0.0608
p 0.1434 0.4284 0.6047 0.6118
 Hypertensionb (r) −0.0669 0.2746 0.0732 −0.0527
p 0.5767 0.0196 0.5413 0.6601
 DM and MGHb (r) −0.1389 0.3076 −0.0206 0.2637
p 0.2445 0.0086 0.8639 0.0252
Newborn
 Weighta (r) 0.2340 −0.1216 −0.1536 0.1097
p 0.0478 0.3089 0.1975 0.3590
 Lengtha (r) −0.1604 −0.2037 −0.1003 0.0750
p 0.1785 0.0862 0.4019 0.5309
 Head  
circumferencea
(r) −0.2704 −0.1373 −0.2194 0.0440
p 0.0216 0.2501 0.0641 0.7133
 Thoracic  
circumferencea
(r) −0.1777 −0.1845 −0.0572 −0.0254
p 0.1354 0.1208 0.6332 0.8325
 Abdominal  
circumferencea
(r) −0.1637 −0.2488 −0.0809 0.0049
p 0.1694 0.0350 0.4991 0.9677
 Ponderal indexa (r) −0.1605 0.0856 −0.1098 0.0655
p 0.1779 0.4744 0.3584 0.5845
Table 4 Multiple regression analysis, p value, for the rela­
tionship between  adipokine/insulin levels and  maternal­
newborn variables
Statistically significant results (p < 0.05) highlighted in italics









Maternal—intercept 0.0348 0.0109 0.0130 0.0452
 Prepregnancy BMI 0.1598 0.9971 0.3654 0.0343
 Gestational BMI 0.1904 0.7297 0.4166 0.0570
 Weight gain 0.1181 0.9258 0.3662 0.0417
 GM at third trimester 0.4076 0.4172 0.8201 0.0894
Newborn—intercept 0.0781 0.0262 0.1369 0.3185
 Weight at birth 0.4478 0.2378 0.5439 0.1291
 Head circumference 0.1904 0.4507 0.1910 0.9480
 Abdominal circumfer-
ence
0.6045 0.0270 0.4548 0.1522
 Ponderal index 0.6533 0.1536 0.7648 0.8645
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According to a recent review, the underlying mecha-
nisms remain largely unknown [43]. Some of these 
mechanisms include the action of adiponectin possibly 
produced by the placenta [44], the role of fetal adiponec-
tin [45], and an antagonistic action of this hormone in the 
placenta inducing insulin resistance [43]. All these factors 
could influence and modulate fetal growth and thus alter 
the expected results of its biomarkers.
Corroborating our controversial findings, no asso-
ciation was found between maternal levels of resistin or 
adiponectin and weight at birth [46]. Some investigators 
suggested that these adipokines are markers of maternal 
diabetes but not of fetal weight [47], and according to 
others, maternal adiponectin levels are inversely related 
to weight at birth in both healthy pregnant women and 
GDM [7, 8, 13]. The maternal milieu compromised by 
overweight or obesity may program fat neonatal accre-
tion, and intrauterine insulin resistance and weight gain. 
In this context, the evaluation of adipokines in maternal 
and cord blood could clarify these questions. This is one 
of our study limitations.
Other limitations in the present study must be consid-
ered. The sample size, probably small, should be mentioned. 
Maternal characteristics, with 66.7  % (48/72) presenting 
hyperglycemic disorders, 45.8 % (33/72) with hypertension, 
and 68.0  % (49/72) with overweight or obesity may have 
influenced the results. Targeted interventions for maternal 
hyperglycemia and overweight or obesity control may have 
also affected our results. The rates of SGA and LGA new-
borns in overweight (22.2  %) and obese (9.7  %) mothers, 
respectively; the small weight gain of overweight or obese 
mothers, and fetal growth markers, similar among groups, 
indirectly reinforce the positive effects of these interven-
tions in our studied population.
Finally, our results have shown an independent asso-
ciation between maternal insulin levels and BMI status. 
Likewise, an independent relationship between mater-
nal leptin and the fetal abdominal circumference was 
defined. To the best our knowledge, these relationships 
have not been presented in the literature yet, pointing 
new perspectives for future research. These results high-
light the need of individualized evaluation considering 
overweight or obese mothers with and without hyper-
glycemic or insulin resistance conditions, not observed 
in most studies. Besides this, they indirectly reinforce 
the positive effects of specific interventions to obese and 
hyperglycemic mothers.
Conclusions
Our findings support the relationship between markers 
of obesity and maternal–fetal outcomes. Maternal insulin 
and adipokines levels showed an independent relation-
ship with respectively mother and newborns outcomes. 
In this studied population, the results indirectly reinforce 
the importance of maternal weight control before and 
during pregnancy to avoid adverse outcomes to mother 
and their newborns.
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